Molecular Pathology of Cancer Group
Search for publications
Only original articles, editorials, guidelines.
-
Garrigós L, Ruiz-Borrego M, Pérez-García JM, Guerrero-Zotano A, Cortés-Salgado A, Kuemmel S, Colleoni M, Reboredo-Rendo C, Bermejo B, Blancas I, Gavila J, Fabi A, Morales C, Stradella A, Carañana V, Martínez-de Dueñas E, Albacar C, Ballesteros-Cidras O, Martrat G, Iacobucci S, Boix O, Berenguer-Molins P, Alcalá-López D, Cortés J, Llombart-Cussac A.
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.
ANNALS OF ONCOLOGY . 37(6): 837-848.
-
Sánchez Gómez R, Pérez-Míes B, Palacios J, Moreno Bueno G, Calvo I, Solorzano JL, Neria F, Fernandez-Abad M, González-Martínez S, García-Estevez L.
Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.
International Journal of Womens Health . 18: 596039-596039.
-
A AC, H AC, V RB, I CB, I RC, H P, J DJ, P I.
Assessment of intratumoral collagen in pituitary neuroendocrine tumors (pituitary adenomas/PitNets) via digital pathology and its correlation with intraoperative consistency.
Pituitary . 29(3): .
-
Rodríguez-Villena A, Schmülling UCV, Zapata IV, Rivas-Fidalgo S, Gión-Cortés M, López-Rodríguez MJ, Carretero-Barrio I, Palacios J, Pérez-Mies B.
Implementation of a Multidisciplinary Protocol for the Safe Handling of Iodine-125 Radioactive Seeds in the Pathology Laboratory.
International Journal of Breast Cancer . 2026: 3962099-3962099.
-
O'Shaughnessy J, Bidard FC, Neven P, Casalnuovo ML, Aftimos P, Saura C, Harbeck N, Carey LA, Curigliano G, Garcia-Saenz JA, Abad MF, Paula L, Park YH, Ozyilkan O, Munoz M, Barrett E, Cao S, Chawla A, Jhaveri KL.
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.
npj Breast Cancer . 12(1): .
-
Perez-Gracia JL, Mellado B, Hansen AR, Alonso-Gordoa T, Gomez-Roca C, Løvendahl Eefsen R, Negrier S, Suárez C, Lee JL, Hussain A, Pedrazzoli P, Moreno V, Rodriguez-Vida A, Sosman JA, Waddell T, Bedke J, Park SH, Sznol M, Spychaj L, Andersson E, Julien-Laferriere A, Cheng WY, Watson C, Silva AP, Heichinger C, Staedler N, Sleiman N, Dejardin D, Boetsch C, Evers S, Vardar T, Ardeshir-Tandon C, Dorado Pérez J, Charo J, Keshelava N, Kraxner A, Teichgräber V, Powles T.
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal for ImmunoTherapy of Cancer . 14(4): .
-
Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Álvarez-Escolá C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yayá Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T.
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
Nature Communications . 17(1): .
-
Moreno-Moreno E, Caniego-Casas T, Ruz-Caracuel I, Carretero-Barrio I, Cabezas-López E, Cortés-Salgado A, Mendiola M, Redondo A, Muriel A, Hardisson D, Palacios J, Pérez-Mies B.
MDM4 amplification as a potential predictor of risk of recurrence in early-stage low-grade endometrial carcinoma.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 104563-104563.
-
Barretina-Ginesta MP, Madariaga A, Gil-Martín M, Ramchandani A, Pardo M, Sanchez-Heras AB, Churruca C, Guerra-Alia EM, Madroñal C, Fernandez-Plana J, Herrero A, Dotor E, Esteban C, Quindós-Varela M, Romeo M, Gost E, Bermejo MJ, Fernandez-Chacón C, Ferrer N, Gomez-Raposo C, Tort SC, Eichbaum M, Sehouli J, Woopen H.
Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 102758-102758.
-
Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, Hernando J, Rodrigo-Calvo MT, Jimenez-Fonseca P, Quiceno-Arias HD, Lorenzo-Lorenzo I, Bella-Cueto MR, Iglesias C, Cameselle-Teijeiro JM, Capdevila J.
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.
Revista Espanola de Patologia . 59(2): 100859-100859. Number of citations: 2
-
Lázaro-Navas I, Mur-Molina B, Villalobos-Baeza EB, Cortés-Salgado A, Pailos RH, Díaz-Soto EM, Fernández-Pardo TE, López-González L, Valcárcel-Linares D.
Effectiveness of radiofrequency therapy combined with pelvic floor muscle training in breast cancer survivors with genitourinary syndrome of menopause: a study protocol.
European Journal of Obstetrics & Gynecology and Reproductive Biology . 320: 115010-115010.
-
Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teulé A, Custodio A, Tafuto S, La Casta A, Spada F, López C, Ibrahim T, Iranzo V, García-Alfonso P, González-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Álvarez G, Soldevilla B, Capdevila J.
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).
JOURNAL OF CLINICAL ONCOLOGY . 44(9): 774-786. Number of citations: 3
-
Tolosa P, García-Fructuoso I, Pascual T, Martínez-Sáez O, Cejalvo JM, Servitja S, Fernández Abad M, Benitez Fuentes JD, Brasó-Maristany F, Sanfeliu E, Lema L, Ruano Y, Parrilla L, Roncero AM, Cobos MÁ, Díaz I, Centelles López KA, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
BREAST CANCER RESEARCH AND TREATMENT . 216(2): .
-
Cerbone L, Roviello G, Calabrò F, Taha T, Grande E, Binz K, Kanesvaran R, Pirstuk A, Fiala O, Molina-Cerrillo J, Alonso-Gordoa T, Rizzo A, Pichler R, Myint ZW, Poprach A, Facchini G, Bohuslav M, Studentova H, Morelli F, Buchler T, Mennitto A, Tural D, Formisano L, Orejana I, Catalano M, Buti S, Monteiro FSM, Soares A, Gupta S, Massari F, Santoni M.
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Frontiers in Immunology . 17: 1667155-1667155.
-
Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D.
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.
Journal for ImmunoTherapy of Cancer . 14(2): . Number of citations: 1
-
Chong AS, Roca C, Morales-Sánchez P, Dorca E, Barea V, Ruz-Caracuel I, Valderrabano P, Rovira C, Jou C, Bouron-Dal Soglio D, Chernock RD, Torrezan GT, Pusztaszeri M, Cameselle-Teijeiro JM, Matias-Guiu X, Alvarez CV, Salvador H, Wasserman JD, Leandro-García LJ, Foulkes WD, Andrés-León E, Casano-Sancho P, Rivera B.
Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions.
JCI Insight . 11(3): .
-
González-Martínez S, Palacios J, Carretero-Barrio I, Fernández-Lanza V, Cortés-Salgado A, Román J, Matias-Guiu X, Gatius S, Cortés J, Pérez-Mies B.
Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.
JOURNAL OF PATHOLOGY . 268(2): 227-242.
-
Casas Gállego VR, Perez Muñoz I, Sanz Pascual MDC, Gonzalez Lizan F, Reguero Callejas ME, Delgado Martínez I.
Extra-axial chordoma in the distal fibula and the importance of ankle reconstruction.
World Journal of Surgical Oncology . 24(1): .